Woodstock Corp Acquires 906 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Woodstock Corp increased its stake in Regeneron Pharmaceuticals by 12.7% in Q2, owning 8,021 shares valued at $4.21 million as of the latest SEC filing.
• The company's stock experienced a 2.2% increase recently, with a current trading price of $572.59 and an average price target of $817.67 from analysts.
• Regeneron reported $12.89 EPS for the last quarter, significantly surpassing the consensus estimate, along with a revenue of $3.68 billion.

Woodstock Corp boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,021 shares of the biopharmaceutical company's stock after purchasing an additional 906 shares during the period. Woodstock Corp's holdings in Regeneron Pharmaceuticals were worth $4,211,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the last quarter. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Finally, Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $6.72 during mid-day trading on Friday, reaching $591.99. 2,177,775 shares of the company were exchanged, compared to its average volume of 1,100,054. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,154.56. The company has a fifty day simple moving average of $567.29 and a 200-day simple moving average of $576.47. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $62.75 billion, a PE ratio of 14.92, a PEG ratio of 1.96 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the company posted $11.56 EPS. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.